Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Esslingen Am Neckar

89 clinical trials in Esslingen Am Neckar, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Esslingen Am Neckar at a glance
89
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

89 trials in Esslingen Am Neckar

Open in trial search

Non-small cell lung cancer+1

Recruiting

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Small cell lung cancer+2

Recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Squamous cell carcinoma of lung+6

Recruiting

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Non-small cell lung cancer

Recruiting

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BeOne Medicines I GmbH

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:WSG Women's Cancer Study Group GmbH

Hodgkin's disease

Recruiting

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:University Of Cologne

Non-small cell lung cancer stage IIIA+2

Recruiting

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+3

Recruiting

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Non-small cell lung cancer

Recruiting

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Esslingen Am Neckar

What the registry says about research in the country

01 Lung Cancer Research

Extensive studies focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating novel treatment combinations and targeted therapies for various disease stages.

  • Advanced and metastatic disease management
  • Post-surgical treatment optimization
  • Combination therapy approaches

Multiple trials investigating immunotherapy combinations and targeted treatments for improved patient outcomes.

02 Breast Cancer Studies

Innovative research targeting hormone receptor-positive and triple-negative breast cancer, exploring new therapeutic strategies and treatment combinations.

  • Early-stage disease management
  • HER2-negative breast cancer
  • Perioperative treatment approaches

Focus on developing personalized treatment strategies and improving survival outcomes.

03 Hematologic Malignancies

Groundbreaking studies in chronic lymphocytic leukemia (CLL) and related blood cancers, evaluating novel drug combinations and treatment duration strategies.

  • Treatment optimization
  • Disease monitoring approaches
  • Targeted therapy combinations

Research aimed at improving treatment responses and patient quality of life.

04 Gastrointestinal Cancers

Research focusing on hepatocellular carcinoma and gastric cancer, investigating innovative combination therapies and surgical approaches.

  • Advanced disease treatment
  • Perioperative therapy
  • Immunotherapy applications

Studies evaluating novel treatment strategies for improved patient outcomes.

05 Gynecologic Oncology

Clinical trials in ovarian cancer and related conditions, studying maintenance therapies and combination treatments for advanced disease.

  • First-line treatment strategies
  • Maintenance therapy optimization
  • Targeted treatment approaches

Focus on improving survival rates and treatment effectiveness.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.